NaB-enhanced hepatic GLP-1R expression via inhibiting HDAC It has been reported that short-chain fatty acids (SCFAs) including NaB are able to regulate the immune response and metabolism through the activation of GPRs, such as GRP43 and GRP109a or through the inhibition of HDAC 27,28
To better accelerate your GLP-1 new drug research and development, GenScript is now offering GLP-1 Receptor Agonist Services
The FDA issued over 80 warning letters to companies marketing compounded GLP-1 products with misleading claims in 2025-2026
A typical approach might look like this: At month -3, you stop semaglutide and begin a basal insulin (for example, Lantus, Levemir, or Tresiba)
Comparing the GLP-1 Pill and the Shot The key to success with a GLP-1 medication is to keep taking it
Watch the GLP-1 Spotlight webinar recording and download the 2025 Trends in Drug Benefit Design Report